School of Advanced Materials Discovery, Colorado State University, Fort Collins, CO, USA.
School of Biomedical Engineering, Colorado State University, Fort Collins, CO, USA.
Nanomedicine. 2019 Oct;21:102046. doi: 10.1016/j.nano.2019.102046. Epub 2019 Jul 3.
The need to improve blood biocompatibility of medical devices is urgent. As soon as blood encounters a biomaterial implant, proteins adsorb on its surfaces, often leading to several complications such as thrombosis and failure of the device. Therefore, controlling protein adsorption plays a major role in developing hemocompatible materials. In this study, the interaction of key blood plasma proteins with superhemophobic titania nanotube substrates and the blood clotting responses was investigated. The substrate stability was evaluated and fibrinogen adsorption and thrombin formation from plasma were assessed using ELISA. Whole blood clotting kinetics was also investigated, and Factor XII activation on the substrates was characterized by an in vitro plasma coagulation time assay. The results show that superhemophobic titania nanotubes are stable and considerably decrease surface protein adsorption/Factor XII activation as well as delay the whole blood clotting, and thus can be a promising approach for designing blood contacting medical devices.
提高医疗器械血液生物相容性的需求迫在眉睫。一旦血液遇到生物材料植入物，蛋白质就会吸附在其表面，这通常会导致血栓形成和器械失效等多种并发症。因此，控制蛋白质吸附在开发血液相容性材料方面起着重要作用。在这项研究中，研究了关键血浆蛋白与超疏水性二氧化钛纳米管基底的相互作用以及血液凝固反应。评估了基底的稳定性，并使用 ELISA 评估了纤维蛋白原吸附和凝血酶从血浆中的形成。还研究了全血凝固动力学，并通过体外血浆凝固时间测定法表征了因子 XII在基底上的激活。结果表明，超疏水性二氧化钛纳米管是稳定的，可大大减少表面蛋白质吸附/因子 XII激活，并延迟全血凝固，因此可能是设计接触血液的医疗器械的一种有前途的方法。
